Patent ID: 7935691

Claim:
A multiphase combination and contraceptive kit comprising a package containing daily dosages of: (a) a Phase I composition containing a progestogen in an amount equivalent to about 0.5 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 30 mcg of ethinyl estradiol; (b) a Phase II composition containing a progestogen in an amount equivalent to about 0.5 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 40 mcg of ethinyl estradiol; and (c) a Phase III composition a progestogen in an amount equivalent to containing about 0.5 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 30 mcg of ethinyl estradiol; wherein the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in each of the Phase I and III compositions, wherein the ethinyl estradiol equivalent amount of estrogen in the Phase III composition is equal to the ethinyl estradiol equivalent amount of estrogen in the Phase I composition, and wherein the sequential administration of the Phase I, II, and III compositions is repeated the day following the completion of the administration of composition III to provide an extended contraceptive cycle, there is no decrease in the norethindrone acetate equivalent amount of progestogen from the administration of the Phase III composition to the administration of the Phase I composition in the extended contraceptive cycle and the extended contraceptive cycle is from about 42 to about 140 days.